Immunotherapy combo eyed as Pre-Surgery option for rare eye cancer

NCT ID NCT07501117

Recruiting now Disease control Sponsor: Inge Marie Svane Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This early-phase trial tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) before eye removal surgery is safe and feasible for people with high-risk uveal melanoma, a rare eye cancer. Fifteen participants will receive the drugs, then have their eye removed. The study will track side effects and how many complete the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to: If this works, it could show that giving immunotherapy before surgery is safe and may help control the spread of uveal melanoma.
What could go wrong: This is a very early, small trial with only 15 people. It focuses on safety and feasibility, not effectiveness. The drugs can cause serious immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UVEAL MELANOMA

Contacts and locations

Locations

National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital
RECRUITING

Herlev, Herlev, 2730, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.